Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908667 | 0.98 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL23665082 | 0.98 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL18908729 | 0.98 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL22054928 | 0.98 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL16674425 | 0.92 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL21740830 | 0.92 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL22054930 | 0.92 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL18855041 | 0.92 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL16674452 | 0.92 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL23665081 | 0.91 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022118186-A1 | SENOTHERAPEUTIC COMPOUND | BIONEXA S.R.L. (IT) | 2022-06-09 | — | — | WO | disclosed |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200323814-A1 | MEDICAL COMPOUND | VERA SALUS RICERCA S.R.L. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| US-9730976-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730976-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2017-08-15 | — | — | US | disclosed |
| US-20160317605-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BIONTECH AG (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160317605-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BIONTECH AG (DE) | 2016-11-03 | — | — | US | disclosed |
| US-9321808-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2016-04-26 | — | — | US | disclosed |
| US-9321808-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20150119342-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-04-30 | — | — | US | disclosed |
| US-20150119342-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317605-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BID, BIRC2, API5 | KMT2A 3320/4885MEN1 1454/4885SMN1; SMN2 190/4885 |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | BRD4, BRD2, BET1 | KMT2A 406/4885MEN1 3402/4885SMN1; SMN2 3861/4885 |
| US-20150119342-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BID, BIRC2, API5 | KMT2A 3320/4885MEN1 1454/4885SMN1; SMN2 190/4885 |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KMT2A 477/4885MEN1 3377/4885SMN1; SMN2 3865/4885 |
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | KMT2A 3455/4885MEN1 426/4885SMN1; SMN2 599/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | KMT2A 3238/4885MEN1 25/4885SMN1; SMN2 1134/4885 |
| US-20200323814-A1 | MEDICAL COMPOUND | MTNR1B, CBR1, MTNR1A | KMT2A 3998/4885MEN1 591/4885SMN1; SMN2 3864/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | KMT2A 1097/4885MEN1 153/4885SMN1; SMN2 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.